Getinge to boost scalability and deepen healthcare access in India

Getinge has a strong market share in India within several product segments

Novartis shares Zolgensma long-term data demonstrating sustained durability up to 7.5 years post-dosing

All children (100%) in the presymptomatic intravenous cohort of LT-002 maintained or achieved all assessed motor milestones, including independent walking

Lonza upgrades powder characterization capabilities at Tampa

The new powder flow tester can characterize powder flow properties, offering valuable insight for pharmaceutical processing and formulation

Pharmapack 2023 a pivotal moment for sustainability in drug delivery and packaging

Nearly 5000 executives and more than 350 exhibitors turned out at the largest post-pandemic pharma packaging event

Lynparza in combination with Abiraterone and Prednisone approved in the EU as treatment for metastatic castration-resistant prostate cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe

Shilpa Medicare introduces cancer drug Capecitabine 1000 MG dispersible tablet

The product is backed by required scientific proof and comparative bioequivalence studies

Lonza collaborates with AbTis to extend Bioconjugation capabilities

Collaboration to implement AbTis’ AbClick platform into Lonza’s bioconjugation toolbox

Lynparza in combination with Abiraterone and prednisone receives positive opinion from EU CHMP

First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations

JB Pharma publishes its maiden sustainability report

Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%

AGC begins study to expand its Bio-CDMO capability in Japan